Many people suffer from constant excessive sweating, not just during sports, hard work or hot weather. This form of sweating affects more than half a million people in the UK alone and is a recognised disease that, however, no one likes to talk about. The so-called “primary hyperhidrosis” is caused by a dysregulation of the sweat glands. This often has a massive impact on the quality of life of those affected, since they are ashamed of large, visible spots of sweat at their clothing, which often tends to repel other people. This makes dating almost impossible and any social contact with friends and relatives as well as to colleagues can`t necessarily be maintained. This not only leads to loneliness, but it can also lead to career problems, up to the point of loss of employment.
Further studies are needed, in order to develop new and better treatment options. If you wish to participate, you can complete this questionnaire, and on basis hereof, you will be contacted, if you are a match for the research project.
Location(s):
- Sutton Coldfield
Reimbursement:
Participating in the study will not entail any extra expense to your usual treatment, as the Sponsor provides the investigational drug and any tests required by the trial. The usual treatment costs will be financed by the sponsor.
Reimbursement within this study:
There will be no additional costs to you due to your participation in this clinical trial. You will receive a flat fee travel expenses reimbursement of € 30 per visit for the expenses incurred by taking part in the study until its termination.
Please note that taxes may need to be paid on this flat fee travel expenses reimbursement; it might also need to be reported to authorities such as the job centre or welfare office.
Who can participate?
- Male and females
- Age: 18 to 65 years
- Diagnosed with severe primary axillary hyperhidrosis
Other criteria may need to be fulfilled before you may pre-qualify for participation in the study. Therefore, to find out if the study may be suitable for you please click on the button below and answer the questionnaire. If you pre-qualify, you and a doctor at the study clinic will determine if this study is suitable for you.
Visits at the site:
During the clinical study, you will have to visit the clinic at specific times. This is in order to perform different assessments, which must be performed at specific time points. The study is divided into two phases (information below).
Phase A (This phase has been completed):
This phase will routinely run for 7 weeks with a total of 5 visits (including screening). (8 weeks in case one repeat visit is needed).
Placebo will be given to 50% of the participants.
Overview of visits in Phase A
If, after the end of phase A you want to participate in phase B, you will receive active treatment for another 68 weeks; and 6 additional visits and one follow up visit 4 four weeks after last treatment; additionally you will need to get to the site every four weeks in order to receive new medication.
Phase B:
Phase B will not start before Phase A has completed.
This phase will run for 79 weeks with a total of 10 main clinic visits.
Placebo is not included in this phase.
Overview of visits in Phase B
The first two visits are screening visits. Which means if you have participated in Phase A you will be starting at visit 5 in Phase B.
About the two phases:
You are not able to select which phase you want to participate in. Phase A will be running from study start and until it has completed. When Phase A is completed Phase B will start.
